Product How it works Pricing Blog FAQ About Contact
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ: ALNY) revenue

Alnylam Pharmaceuticals reported revenue of $3,714m for fiscal 2025, 65.2% more than in fiscal 2024 ($2,248m). Since fiscal 2016 its revenue has grown by 7,775.4%, an average growth of 62.4% a year.

Alnylam Pharmaceuticals has grown its revenue for 7 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2018, −16.7%.

Revenue, in millions of US dollars47.2201689.9201774.92018219.82019492.92020844.320211,03720221,82820232,24820243,7142025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$3,714m+65.2%$501.6m13.5%
2024$2,248m+23.0%−$176.9m−7.9%
2023$1,828m+76.2%−$282.2m−15.4%
2022$1,037m+22.9%−$785.1m−75.7%
2021$844.3m+71.3%−$708.7m−83.9%
2020$492.9m+124.3%−$828.4m−168.1%
2019$219.8m+193.4%−$939.4m−427.5%
2018$74.9m−16.7%−$814.7m−1,087.6%
2017$89.9m+90.7%−$500.1m−556.2%
2016$47.2m—−$424.6m−900.3%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Alnylam Pharmaceuticals revenue compared with its sector

By revenue for its latest fiscal year, Alnylam Pharmaceuticals ranks 76th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Alnylam Pharmaceuticals, 65.2%.

RankCompanyRevenueRevenue growth
74thAlignment Healthcare$3,949m46.1%
75thAptarGroup$3,777m5.4%
76thAlnylam Pharmaceuticals$3,714m65.2%
77thDentsply Sirona$3,680m−3.0%
78thBruker$3,437m2.1%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Alnylam Pharmaceuticals

How much revenue did Alnylam Pharmaceuticals make in fiscal 2025?
Alnylam Pharmaceuticals reported revenue of $3,714m for fiscal 2025, compared with $2,248m in fiscal 2024.
How much has the revenue of Alnylam Pharmaceuticals grown?
Between fiscal 2016 and fiscal 2025 it went from $47.2m to $3,714m: 7,775.4% more, an average growth of 62.4% a year.
What was the best year for revenue at Alnylam Pharmaceuticals?
Of its last 10 fiscal years, fiscal 2025, with $3,714m.
Where does Alnylam Pharmaceuticals rank in its sector by revenue?
It ranks 76th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Alnylam Pharmaceuticals come from?
From the annual report (Form 10-K) that Alnylam Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Alnylam Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Alnylam Pharmaceuticals: the Alnylam Pharmaceuticals page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.